Table 2 CD47-related clinical trials registered in the China drug trials registry (CDT) system www.chinadrugtrials.org.cn
Agent | CD47 Isotype | Organization | Mechanism of action | CDT Number | Status | Conditions | Phase | Enrollment | Start date |
|---|---|---|---|---|---|---|---|---|---|
IMM0306 | IgG1 | ImmuneOnco | Bi-specific mAb-Trap CD47 and CD20 | CTR20192612 | Recruiting | R/R NHL, CD20 +  | Phase 1 | 42 | 23-Mar-20 |
HX009 | IgG4 | Hanxbio | Bi-specific mAb CD47 and PD-1 | CTR20211292 | Recruiting | Advanced solid tumor | Phase 2 | 210 | 12-Jul-21 |
SHR-1603 | IgG4 | Jiangsu HengRui Medicine | CD47 mAb | CTR20181964 | Suspended | Advanced Solid Tumors | Phase 1 | 128 | 5-Nov-18 |
TJ011133 | IgG4 | I-MAB Biopharma | CD47 mAb | CTR20210313 | Recruiting | R/R advanced solid tumors, NHL | Phase 1 | 50 | 18-Mar-21 |
CTR20192522 | Recruiting | R/R AML, MDS | Phase 1/2 | 42 | 19-Dec-19 | ||||
CTR20210555 | Recruiting | AML, MDS | Phase 1/2 | 60 | 29-Mar-21 | ||||
ZL-1201 | IgG4 | Zai Lab | CD47 mAb | CTR20210973 | Recruiting | Advanced solid tumor | Phase 1 | N/A | 7-May-21 |
AK117 | IgG4 | Akesobio | CD47 mAb | CTR20202684 | Recruiting | Advanced solid tumors, NHL | Phase 1 | 162 | 29-Dec-20 |
CTR20210825 | Recruiting | MDS | Phase 1/2 | 190 | 12-May-21 | ||||
CTR20211305 | Active, not Recruiting | AML | Phase 1/2 | 160 | 4-Jun-21 | ||||
IBI188 | IgG4 | Innovent Bio | CD47 mAb | CTR20210761 | Recruiting | Advanced solid tumor | Phase 1 | 120 | 12-Apr-21 |
CTR20182140 | Completed | Advanced Solid Tumors | Phase 1 | 49 | 22-Nov-18 | ||||
CTR20200938 | Recruiting | AML | Phase 1/2 | 222 | 30-Jul-20 | ||||
CTR20201039 | Recruiting | MDS | Phase 1/3 | 338 | 23-Jul-20 | ||||
IMM01 | N/A | ImmuneOnco | SIRPα Fc fusion protein targeting CD47 | CTR20191531 | Recruiting | R/R NHL | Phase 1 |  | 20-Aug-19 |